Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
Additional data from the RESCUE-ALS open-label extension were presented in a late breaker session at the American Academy of Neurology Annual Meeting (April 2022).
- Additional data from the RESCUE-ALS open-label extension were presented in a late breaker session at the American Academy of Neurology Annual Meeting (April 2022).
- Unblinded data from the VISIONARY-MS Phase 2 clinical trial data are targeted for the third quarter of 2022.
- Clene expects that its cash as of March 31, 2022, will be sufficient to fund its operations into the second quarter of 2023.
- Research and development expenses were $8.6 million for the quarter ended March 31, 2022, compared to $6.3 million for the same period in 2021.